Get started
NOVO-NORDISK AS B DK 0,1NOVO-NORDISK AS B DK 0,1NOVO-NORDISK AS B DK 0,1

NOVO-NORDISK AS B DK 0,1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NOV trade ideas

Long Term: looking for an entry point on this beautiful stockNovo Nordisk is one of the world leaders in the medical treatment of diabetes. It also researches, develops and markets treatments for obesity. It is a fast-growing sector with the rise of fast food and the development of emerging countries. However, the field is becoming more and more competitive, especially in the US, which has meant slower growth for the future of Novo Nordisk. Until now, she was considered a "cash cow". Let's see if I can drink her milk :-)
OMXCOP:NOVO_BLong
by sharl92
NVO Breakout to All-Time HighIn this chart we're looking at NVO on the 1W chart as price has consolidated into an ascending triangle . Price has broken through the horizontal boundary around $58. After price prints a 1W candle (1 day left) through $59.77 breakout will be confirmed. This ascending triangle has a price target of around $85 for about a ~46% gain. Price has good momentum as it has found support on the 200EMA and is breaking out of its chart pattern boundary well above the 200EMA. If you would like to see more of these ideas on a regular basis, follow me as I will be posting many more exciting chances to earn on chart pattern breakouts this upcoming year! Drop a like or comment if you found this idea informational or helpful in any way! Cheers!
NYSE:NVOLong
by TheLuckyS7ven
$NVO Breakout possible for Nova NordiskEntry level $59.50 = Target price $65.50 = Stop loss $57.60 Stock is on the verge of a multiyear breakout from 2015. Ascending triangle formation bullish. Odds are that the stock breaks out rather than make a triple top. P/E ratio 23. Company profile Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
NYSE:NVOLong
by Bullishcharts